Cantor initiated Amgen (NASDAQ:AMGN) coverage with an overweight rating, asserting it was a “big believer” in the biotech ...
Amgen on Tuesday reported that a pair of antibody drugs it is developing as treatments for immune-mediated diseases succeeded ...
As for Uplizna, Amgen said that it is initiating regulatory filing activities to set it up for approval to treat MG. Last ...
Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...
Beyond MariTide, Amgen has a rich pipeline with more than 30 phase 3 programs. Some are for existing medicines seeking label ...
Regeneron cannot immediately block U.S. sales of rival Amgen's proposed copy of its blockbuster eye-care drug Eylea, a ...
On 4, 2024, Amgen, Inc. filed a notice of data breach with the Attorney General of Massachusetts after discovering that ...
In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna ...
Amgen said on Tuesday that its drug helped improve daily activities including chewing and swallowing in patients suffering ...
Amgen (AMGN) stock slid more than 4.5% at the start of Wednesday trading after the pharmaceutical giant reported the results ...
Insights from analysts' 12-month price targets are revealed, presenting an average target of $326.38, a high estimate of $381 ...
Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback